- Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–515. doi:10.1038/nrcardio.2014.832.
- Vachiéry JL, Adir Y, Barberà JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D100–D108. doi:10.1016/j.jacc.2013.10.0333.
- Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. doi:10.1161/CIR.0000000000000558.
- Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122(3):216–238. doi:10.1016/j.pharmthera.2009.02.009.
- Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018;104(15):1244–1250. doi:10.1136/heartjnl-2017-312865.
- Kovács Á, Alogna A, Post H, Hamdani N. Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? Netherlands Heart J. 2016;24(4):268–274. doi:10.1007/s12471-016-0814-x.
- Emdin M, Aimo A, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(15):1795–1807. doi:10.1016/j.jacc.2020.08.031.
- Hwang IC, Kim YJ, Park JB, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;17(1):150. doi:10.1186/s12872-017-0576-4.
- Park M, Sandner P, Krieg T. cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. Basic Res Cardiol. 2018;113(4):24. doi:10.1007/s00395-018-0679-9.
- Redfield MM, Chen HH, Borlaug BA, et al; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268–1277. doi:10.1001/jama.2013.2024.
- Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36(38):2565–2573. doi:10.1093/eurheartj/ehv336.
- Andersen MJ, Ersbøll M, Axelsson A, et al. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation. 2013;127(11):1200–1208. doi:10.1161/CIRCULATIONAHA.112.000056.
- Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovasc Disord. 2020;20(1):408. doi:10.1186/s12872-020-01671-2.
- Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124(2):164–174. doi:10.1161/CIRCULATIONAHA.110.983866.
- Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4(8):607–616. doi:10.1016/j.jchf.2016.03.022.
- Opitz CF, Hoeper MM, Gibbs JSR, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol. 2016;68(4):368–378. doi:10.1016/j.jacc.2016.05.047.
- Kramer T, Dumitrescu D, Gerhardt F, et al. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol. 2019;283:152–158. doi:10.1016/j.ijcard.2018.12.078.
- Mitter SS, Shah SJ, Thomas JD. A test in context: E/A and E/e' to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol. 2017;69(11):1451–1464. doi:10.1016/j.jacc.2016.12.037.
- Dabestani A, Mahan G, Gardin JM, et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol. 1987;59(6):662–668. doi:10.1016/0002-9149(87)91189-1.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 5
Review Article
Meta-analysis examining phosphodiesterase-5 inhibitors in heart failure with preserved ejection fraction
Govinda Adhikaria Department of Internal Medicine, McLaren-Flint/Michigan State University, Flint, MichiganCorrespondence[email protected]
https://orcid.org/0000-0002-0780-9385
, MDhttps://orcid.org/0000-0002-0780-9385, Nischit Barala Department of Internal Medicine, McLaren-Flint/Michigan State University, Flint, Michiganhttps://orcid.org/0000-0001-5349-7127
, MDhttps://orcid.org/0000-0001-5349-7127, , MD, Gary Tseb Kent and Medway Medical School, Canterbury, UKhttps://orcid.org/0000-0001-5510-1253
, MD, PhDhttps://orcid.org/0000-0001-5510-1253, , MD, Basel Abdelazeema Department of Internal Medicine, McLaren-Flint/Michigan State University, Flint, Michiganhttps://orcid.org/0000-0002-2919-6196
, MDhttps://orcid.org/0000-0002-2919-6196, , MD, Pramod Savarapua Department of Internal Medicine, McLaren-Flint/Michigan State University, Flint, Michiganhttps://orcid.org/0000-0001-6614-2229
, MDhttps://orcid.org/0000-0001-6614-2229, , MD, , MD & , MD show all